Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a TurnaroundZacks Investment Research • 08/16/23
FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/08/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the FirmAccesswire • 07/25/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/21/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/19/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGENPRNewsWire • 07/17/23
FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 07/14/23
Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a TurnaroundZacks Investment Research • 07/11/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/08/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/03/23
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Fibrogen, Inc. and Encourages Investors With Losses to Contact the FirmBusiness Wire • 06/27/23
FibroGen's Unsteady Course: Assessing Fallout From IPF Failure And The Road AheadSeeking Alpha • 06/26/23
FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead DrugInvestors Business Daily • 06/26/23
FibroGen to discontinue late-stage trial of treatment for idiopathic pulmonary fibrosis, cut costs to extend cash runway to 2026Market Watch • 06/26/23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewsWire • 06/26/23